Cargando…
Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)
INTRODUCTION: Concurrent chemoradiation is the standard therapy for patients with local advanced oesophageal carcinoma unsuitable for surgery. Paclitaxel is an active agent against oesophageal cancer and it has been proved as a potent radiation sensitiser. There have been multiple studies evaluating...
Autores principales: | Ai, Dashan, Chen, Yun, Liu, Qi, Zhang, Junhua, Deng, Jiaying, Zhu, Hanting, Ren, Wenjia, Zheng, Xiangpeng, Li, Yunhai, Wei, Shihong, Ye, Jinjun, Zhou, Jialiang, Lin, Qin, Luo, Hui, Cao, Jianzhong, Li, Jiancheng, Huang, Guang, Wu, Kailiang, Fan, Min, Yang, Huanjun, Zhu, Zhengfei, Zhao, Weixin, Li, Ling, Fan, Jianhong, Badakhshi, Harun, Zhao, Kuaile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196866/ https://www.ncbi.nlm.nih.gov/pubmed/30344165 http://dx.doi.org/10.1136/bmjopen-2017-020785 |
Ejemplares similares
-
A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma—the ESO-shanghai 1 trial protocol
por: Chen, Yun, et al.
Publicado: (2018) -
Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial
por: Ai, Dashan, et al.
Publicado: (2022) -
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial
por: Chen, Yun, et al.
Publicado: (2019) -
A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021) -
Dose escalation based on (18)F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)
por: Zhu, Hongcheng, et al.
Publicado: (2022)